GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (FRA:27F0) » Definitions » Institutional Ownership

Kala Bio (FRA:27F0) Institutional Ownership : 3.13% (As of May. 06, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kala Bio's institutional ownership is 3.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kala Bio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kala Bio's Float Percentage Of Total Shares Outstanding is 91.76%.


Kala Bio Institutional Ownership Historical Data

The historical data trend for Kala Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Institutional Ownership Chart

Kala Bio Historical Data

The historical data trend for Kala Bio can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 2.66 2.66 2.61 2.31 2.17 2.17 2.10 2.67 3.13 3.13

Kala Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Kala Bio (FRA:27F0) Business Description

Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio (FRA:27F0) Headlines

No Headlines